Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

p>REPLAGAL - for the treatment of Fabry disease

  • On June 24, 2011 Shire announced that the European Medicines Agency has approved the purification of REPLAGAL drug substance at its new manufacturing facility in Lexington, MA. REPLAGAL is the first product that will be made available to patients from the new facility. With this approval, Shire now has two approved facilities for the production of Human Genetic Therapies ("HGT") products - Alewife, which is located in Cambridge, MA, and the new Lexington facility. This provides increased manufacturing flexibility for REPLAGAL.

VPRIV - for the treatment of Type 1 Gaucher disease

  • Shire's continuing priority is to ensure long-term, uninterrupted treatment for patients with Type I Gaucher disease with VPRIV at the approved dose and frequency prescribed by their physician. Shire continues to meet all requested demand for VPRIV globally and continues to supply the product to new patients - either naïve to therapy or those switching from different therapies. Shire can continue to meet all anticipated demand for VPRIV globally. We are working to obtain approval of the new manufacturing facility in Lexington for VPRIV which will provide substantial additional manufacturing capacity. Process validation runs are currently ongoing.

INTUNIV® - for the treatment of ADHD

  • On April 4, 2011, following approval by the FDA on February 28, 2011, Shire launched once-daily INTUNIV extended-release tablets as adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents aged 6 to 17 as part of a total treatment program.

MEZAVANT - for the treatment of ulcerative colitis

  • On June 7, 2011 following approval by Health Canada on February 10, 2011 Shire announced the lau
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Data to be presented at American Society of Anesthesiologists Annual ... continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor with ... ... Calif., Oct. 17 Masimo, the inventor,of Pulse CO-Oximetry(TM) and ...
... announced today a significant redesign of its web site, including ... database of published synthetic gene applications and a revamped Bioinformatics ... DNA and protein sequences. , ... ...
... Shandong, China, Oct. 17 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, ... Company,), a leading manufacturer and distributor of ... announced that it has,completed factory improvements providing ... cornstarch facility., The Company,s improvement of ...
Cached Biology Technology:Five New Clinical Studies Show Value of Masimo PVI & PI 2Five New Clinical Studies Show Value of Masimo PVI & PI 3Five New Clinical Studies Show Value of Masimo PVI & PI 4Five New Clinical Studies Show Value of Masimo PVI & PI 5DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 2Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 3
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... Unisys Nederland N.V., today announced that it has been selected ... and manage a new Basic Provision Biometrics solution for penitentiaries ... Unisys won the contract with a solution based on its ... The term of the contract is up to seven years, ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
... Building on these findings, the Helmholtz scientists and their ... pathogenesic mechanisms of the disease and gain perspectives for ... study have been published online in the journal ... international research consortium QTSCD (QT Interval and Sudden Cardiac ...
... cholesterol level, working out on his treadmill. The ... his heart,s electrical system had managed to stay on the ... sudden cardiac death, which annually claims more than a quarter ... detectable molecules circulating in the blood makes the prediction of ...
... Technology and Innovation in Global BiometricsGAITHERSBURG, Md., March ... ) has been named the Biometrics Systems Integrator ... recognizing the Corporation,s leadership in developing innovative biometrics ... and Sullivan based the award on a rigorous ...
Cached Biology News:Genetic risk factors identified for sudden cardiac death 2Genetic risk factors identified for sudden cardiac death 3Hopkins scientists ID 10 genes associated with a risk factor for sudden cardiac death 2Hopkins scientists ID 10 genes associated with a risk factor for sudden cardiac death 3Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2
...
... Polymerase gene from Thermus aquaticus (strain ... E. coli, then highly purified to ... used in the amplification and sequence ... quality of the Taq DNA polymerase ...
Rabbit polyclonal to hnRNP-U...
... DNase I (RNase-free) (E.C. 3.1.21.1) is a ... and chromatin. It functions by hydrolyzing phosphodiester ... 5'-phosphate and a 3'-hydroxyl group. Ambion's RNase-free ... available and is recommended to degrade DNA ...
Biology Products: